Tuesday, June 5, 2012

CRIMINAL JUSTICE - DRUG ABUSE TREATMENT STUDIES - Home

The National Institute on Drug Abuse (NIDA) established CJ-DATS as a cooperative research program to explore the issues related to the complex system of offender treatment services. Research centers and a Coordinating Center were created in partnership with researchers, criminal justice professionals, and drug abuse treatment practitioners to form a national research infrastructure.
"The establishment of CJ-DATS is an outstanding example of cooperation among Federal agencies with the research community... We need to understand how to provide better drug treatment services for criminal justice offenders to alter their drug use and criminal behavior."
- Dr. Nora Volkow, Director of NIDA.
CJ-DATS is one of the research networks in the NIDA Networking Project.

CJ-DATS PHASE I
In 2002, NIDA launched the National Criminal Justice—Drug Abuse Treatment Studies (CJ-DATS). CJ-DATS is a multisite research program aimed at improving the treatment of offenders with drug use disorders and integrating criminal justice and public health responses to drug involved offenders. From 2002 through 2008, CJ-DATS researchers from 9 research centers, a coordinating center, and NIDA worked together with federal, state, and local criminal justice partners to develop and test integrated approaches to the treatment of offenders with drug use disorders. The areas that were studied included:

Assessing Offender Problems
Measuring Progress in Treatment and Recovery
Linking Criminal Justice and Drug Abuse Treatment
Adolescent Interventions
HIV and Hepatitis Risk Reduction
Understanding Systems

CJ-DATS PHASE II
In 2008, CJ-DATS began to focus on the problems of implementing research-based practices drug treatment practices. This research concerns the organizational and systems processes involved in implementing valid, evidence-based practices to reduce drug use and drug-related recidivism for individuals in the criminal justice system. 12 CJ-DATS Research Centers are conducting implementation research in three primary domains:

Research to improve the implementation of evidence-based assessment processes for offenders with drug problems
Implementing effective treatment for drug-involved offenders
Implementing evidence-based interventions to improve an HIV continuum-of-care for offenders

Overview of the Criminal Justice Drug Abuse Treatment Studies
Prendergast, M. (2006). Overview of the Criminal Justice Drug Abuse Treatment Studies. Clinical Trials Network Steering Committee Meeting
National Criminal Justice Drug Abuse Treatment Studies (CJ-DATS): Update and Progress
Fletcher, B., & Wexler, H. National Criminal Justice Drug Abuse Treatment Studies (CJ-DATS): Update and Progress. JRSA The Forum, 23, 1-7.

Alcohol and drug problems would be categorized differently in revised manual - The Washington Post

Alcohol and drug problems would be categorized differently in revised manual

By Michelle Andrews, Published: May 28

What’s in a name? That’s a question that experts are wrestling with as they prepare to revise the diagnostic manual that spells out the criteria for addiction and other substance-use problems.

The catalyst for this discussion is a set of proposed changes to the Diagnostic and Statistical Manual of Mental Disorders, the reference guide upon which clinicians, researchers, insurers and others rely to identify and classify psychiatric disorders. The revised guide, called DSM-5, will incorporate changes to more than a dozen categories of disorders, including those related to mood, eating and personality, as well as substance use and addiction.

Developed under the auspices of the American Psychiatric Association, the revised manual is scheduled for release in May 2013.

The new guidelines would do away with the diagnostic categories of “substance abuse,” which generally is defined by such short-term problems as driving drunk, and “substance dependence,” which is chronic and marked by tolerance or withdrawal. They would be replaced by a combined “substance use and addictive disorders” category.

They would also, for the most part, merge the criteria used to diagnose disorders related to the use of alcohol, cigarettes, illicit or prescription drugs and other substances into a single 11-item list of problems typically associated with these disorders. The list covers issues such as being unable to cut down or control the use of that substance and failing to meet obligations at work, school or home.

People would be given a diagnosis based on how many criteria on that list they met: no disorder (0-1), mild disorder (2-3), moderate (4-5) or severe (6 or more).

Supporters say the proposed changes, by creating a category for mild disorders, may make it easier to identify and address drug or alcohol problems before they become serious.

According to the National Institute on Alcohol Abuse and Alcoholism, people are at risk for developing a substance use disorder if their drinking exceeds four drinks on any single day and more than 14 drinks per week for men, and three drinks on any single day and more than seven drinks per week for women.

People who routinely drink heavily at sporting events or regularly get high with friends may be at risk for a substance use disorder, but they generally don’t need lengthy treatment to change their ways, experts say. The new DSM guidelines might make it easier for primary-care doctors to be reimbursed by insurers for screening for alcohol and drug problems and conducting short counseling sessions that have been shown to be effective.

The goal is to educate patients about the higher risks they face of, for example, having a car accident or liver problems if they drink, and to motivate them to change, says Keith Humphreys, a psychiatry professor at Stanford University and a former senior drug policy adviser to the Obama administration.

“A lot of times, people aren’t aware that their consumption is way higher than average,” he says. “If you tell people they drink more than others, they can change and avoid the consequences.”

The U.S. Preventive Services Task Force also recommends screening and behavioral counseling to reduce alcohol misuse in adults. Under the federal health law adopted in 2010, it’s covered as a free preventive benefit for people in health plans that are new or have changed enough to lose their grandfathered status.

But some addiction experts worry that using the 11-point list of criteria to place substance use disorders on a continuum from mild to severe suggests that there’s a natural escalation from non-use to occasional use to risky use to addiction.

“I think that’s not consistent with clinical research,” says Eric Goplerud, who directs the substance abuse, mental health and criminal justice studies department at NORC, a research organization at the University of Chicago.

It’s analogous to depression, he says. “People are sad when bad things happen to them, but not all are on an escalator that will lead them to psychotic depression.”

Because the new guidelines use a single spectrum for substance use and addictive disorders, some addiction experts worry that, for example, adolescents who meet the criteria for mild substance use because they’ve engaged in binge drinking and missed classes because of it within the past 12 months — thereby earning a score of 2 — might be labeled as having a mild addictive disorder, which in many cases would not be accurate.

Some may resist treatment if they are labeled addicts, says Yifrah Kaminer, a professor of psychiatry and pediatrics at the University of Connecticut Health Center. “Adolescents vehemently don’t like stigmatization,” he says. “They’ll say, ‘This treatment is only for addicts, and I don’t want to go.’ ”

Even though the Mental Health Parity and Addiction Equity Act of 2008 requires insurers to cover mental and physical health services equally, “people still have to fight for addiction treatment,” says Marvin Seppala, chief medical officer at Hazelden, a Minnesota nonprofit that runs drug and alcohol treatment centers around the country. The parity law doesn’t cover group plans at companies with 50 or fewer employees, nor individual health insurance plans.

One of the longest running programs, however, doesn’t require insurance because it’s free: Alcoholics Anonymous.

This column is produced through a collaboration between The Post and Kaiser Health News. KHN, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health-care-policy organization that is not affiliated with Kaiser Permanente. E-mail: questions@kaiserhealthnews.org.

Topic Review: ADDICTIONS - | PsychiatryOnline | FOCUS | Issue Table of Contents | Other Sources

Topic Review: ADDICTIONS

Addiction - From Wikipedia

Substance dependence - From Wikipedia

See also

Questionnaires

Opium - From Wikipedia

____________________________________________

PsychiatryOnline | FOCUS | Issue Table of Contents

All Issues

Topics

In This Issue

< Previous Issue | Next Issue >

FOCUS
Addiction: Current and Future Treatments
Winter 2011, Vol. 9, No. 1

Get Alert | RSS

Download PDFs: Cover Table of Contents Editorial Board Front Matter Back Matter Complete Issue Print Advertising

FROM THE GUEST EDITOR

From the Guest Editor

Joyce A. Tinsley, M.D.

MOC Component	APA Resource	Credit(s)	Cost
Self-Assessment	FOCUS Self-Assessment	24	FOCUS Subscription ■ 800.368.5777
	2012 APA Annual Meeting Self-Assessment in Psychiatry - Available until May 30, 2012	8	Free to Annual Meeting Registrants $100 Members/ $200 Non-Members
	FOCUS MOC Workbook, Self-Assessment in Major Depressive Disorder** - Available in June	12	TBD
	eFOCUS Program (sent via email)	Up to 8 hrs per year	FOCUS Subscribers- Free APA Members - Free
Performance in Practice (PIP)	Physician Practice Assessment Tool for Screening of Adults with Substance Use Disorder - Available Now in FOCUS & online	20	FOCUS Subscribers - Free APA Members - Free Non-members - $399
	Physician Practice Assessment Tool for Assessment and Treatment of Adults with Substance Use Disorder -Available Now in FOCUS & online	20	FOCUS Subscribers - Free APA Members - Free Non-members - $399
	Physician Practice Assessment Tools for Assessment and Treatment of Adults at Risk for Suicide and Suicide-Related Behaviors -Available now in FOCUS & online	20	FOCUS Subscribers - Free APA Members - Free Non-members - $399
	Physician Practice Assessment Tool for the Care of Patients with a Diagnosis of Schizophrenia -Available now in FOCUS & online summer 2012	20	FOCUS Subscribers - Free APA Members - Free Non-members - $399
	Physician Practice Assessment Tool for the Care of Patients with Major Depressive Disorder -Available in print (MOC Workbook)* in June & online Fall 2012*	20	FOCUS Subscribers –Free APA Members - Free Non-members - $399 Pricing TBD - FOCUS MOC Workbook
Examination Preparation	FOCUS Psychiatry Review Volume 2	50	Non-members - $65 APA Members - $52 Members-in-Training – $48.75
Examination Preparation	FOCUS Psychiatry Review	50	Non-members - $65 APA Members - $52 Members-in-Training – $48.75


PROGRAM GUIDE	NIAAA BROCHURE	NIDA BROCHURE

COURSE BROCHURE	LECTURER BROCHURE	ETHICS BROCHURE

SYLLABUS BOOK	MILITARY BROCHURE	NEW RESEARCH BOOK

2010 APA Annual Meeting Online - DVD-ROM and Online content summary*

Saturday, May 22
ISS 01	New Developments in Schizophrenia Research and Practice: From the Pipeline to the Clinic
Lecture 01	Translational Research in Schizophrenia: Challenges and Promises
Lecture 02	The Future of Depression Research
Presidential Symposium 1	The Emerging Neurobiology of Antidepressant Treatment Response
Symposium 002	Recent Research on Eating Disorders
Symposium 006	Update on Treatments for Child and Adolescent Eating Disorders
Symposium 007	Neurodevelopmental Disorders in DSM-V: An Update from the Work Group
Symposium 009	Advances in the Management of Treatment-Resistant Depression
Symposium 012	Anxiety Treatment: New Research Findings for the Clinician
Symposium 015	Spirituality and Mental Health: What is the Psychiatrist's Role?
Symposium 020	Updating the APA Guidelines for the Treatment of Borderline Personality Disorder
Symposium 027	Non Psychotic Issues of Schizophrenic Patients
Symposium 029	Executive Function as a Brain System for Self-Control: The Neurocircuitry of Psychiatric Disorders and Addiction
Symposium 030	Addiction Research, Prevention and Treatment in the U.S. and France: Vive la Difference!

Sunday, May 23
Lecture 03	Manfred S. Guttmacher Award Lecture: Patient Violence Against Mental Health Clinicians: Safety Assessment and Prevention
Symposium 031	Understanding Personality Disorders in Children and Adolescents: Current Status and Future Directions
Symposium 032	Treatment of Depression in Ethnic Minorities
Symposium 033	Approaches to Schizophrenia Through Phases of the Illness
Symposium 034	Diagnosing and Treating the Narcissistic Personality Disorder: Awaiting DSM-5
Symposium 035	Sex/Gender Differences and Women-Specific Issues in Drug Abuse: Predicting and Improving Treatment Outcomes
Symposium 036	Treating Chronic Pain and Co-Occuring Addiction in Substance Abuse Patients
Symposium 037	Culturally Sensitive Treatment of Psychologically Distressed Ethnic and Non-English Speaking Populations
Symposium 038	Neuroendocrine and Neuroimmunological Correlates of Bipolar Disorder in Women
Symposium 039	The Medical Home: Is There a Place for Psychiatry in it?
Symposium 040	Privacy in Electronic Medical Records

Monday, May 24
Advances In Series 02	Advances in Psychosomatic Medicine
Advances In Series 04	Advances in Psychotherapeutic Treatments
Advances in Medicine 02	Top 10 Medical Articles of 2009: A Comprehensive and Practical Review of What We Need to Know
Focus	Focus Live 1 - Psychotherapy
ISS 02	Novel Approaches to Assessing and Treating Depression in the Medically-Ill
Lecture 04	APA/NIMH Vestermark Award Lecture - Why I Teach - Glen Gabbard, M.D.
Lecture 05	Distinguished Psychiatrist Lecture - The Perplexities & Provocations of Eating Disorders - Katherine Halmi, M.D.
Lecture 06	Optogenetics - Development and Application - Karl Deisseroth, M.D., Ph.D.
Lecture 08	Adolf Meyer Award Lecture - The Audacity Principle in Science?
Lecture 10	The Simple Truth About the Genetic Complexity of Schizophrenia
Presidential Symposium 2	Comparative Effectiveness of Psychotropic Drugs: What Can We Learn from Practical Clinical Trials?
Presidential Symposium 3	Can Basic and Translational Neuroscience Improve Treatment in Psychiatry?
Symposium 049	Advances in the Treatment of Bipolar Disorder
Symposium 053	Genotypes and Biomarkers: The New Decision Makers for Tailored Treatment
Symposium 059	Neurobiology of Obesity: Why We Can Get Too Motivated to Eat

Tuesday, May 25
Advances In Series 08	Advances In Personality Disorders
Advances in Medicine 03	Movement Disorders in Psychiatric Patients
Lecture 13	From Circuits to Cells to Molecular Regulation: Identifying Novel Targets for the Treatment of Psychotic Disorders
Lecture 14	Co-Morbidity of Psychiatric Disorders
Lecture 15	Highlights and Lessons from 40 Years in Psychiatry
Lecture 16	New Directions in Drug Policy: President Obama’s National Demand Reduction Priorities - Special Guest Lecture, National Institute on Drug Abuse
Lecture 18	Prevention Initiatives in Schizophrenia
Lecture 19	Depression and Suicidal Behavior in Latino Populations - Simon Bolivar Award Lecture
Presidential Symposium 4	Recent Advances in Psychiatric Genetics: From Fundamental Discovery to Clinical Implication
Symposium 065	DSM-5 Examined: Nosology of Mood Disorders
Symposium 068	Reward Neurocircuitry in Substance Dependence and Other Psychiatric Disorders: What Does Brain Research Tell Us?
Symposium 070	Evidence-Based Treatments (EBT) for Borderline Personality Disorder: Empirical Clarity Meets Clinical Reality
Symposium 074	The Treatment of Psychiatric Disorders with rTMS: New Research and Clinical Findings
Symposium 079	The Challenge of Cognitive Enhancers in Medicine

Wednesday, May 26
Lecture 20	Administrative Psychiatry Award Lecture - So You Want to be a Physician Executive - Arthur Lazarus, M.D., M.B.A.
Lecture 21	Seek and Treat for Optimal Prevention of HIV/AIDS: STOP HIV/AIDS - Julio Montaner, M.D.
Symposium 086	How Dysfunction of Learning and Memory Circuits Contribute to Substance Abuse and Other Psychiatric Disorders
Symposium 088	ADHD FAQs: Practical Answers for the Office-Based Practicioner
Symposium 089	Autonomy in the Prolongation and Curtailment of Life
Symposium 090	New Perspectives on Intergenerational Transmission of BPD
Symposium 100	Dysfunctions in Mentalization or Metacognition in Personality Disorders: Empirical Evidence and Implications for Pathology, Treatment and Research
Symposium 103	Comprehensive HIV Psychiatry Update
Symposium 104	Understanding Comorbidity of Heart Disease With Depression and Anxiety Disorders
Symposium 105	The Ethics of Innovative Interventions in Psychiatry

*Tentative content. Subject to change. Industry-Supported Symposia will be available ONLINE only CME credit for all programs available online. Individual sessions will be available as audio MP3 file downloads post-meeting at www.marathonmultimedia.com/store/apaThe American Psychiatric Association is accredited by the ACCME to provide continuing medical education for physicians. you may have. The APA designates each of the sessions in this educational activity for a maximum of 1-3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

2010 APA Annual Meeting - Audio DVD-ROM content summary*

Saturday, May 22
Lecture 01	Translational Research in Schizophrenia: Challenges and Promises
Lecture 02	The Future of Depression Research
Presidential Symposium 1	The Emerging Neurobiology of Antidepressant Treatment Response
Seminar 01	Managing Malpractice Risk for Psychiatrists: The Basics and Beyond
Seminar 02	Evidence-Based Psychotherapy for Chronic Major Depression
Seminar 03	Managing Malpractice Risk for Psychiatrists: The Basics and Beyond
Seminar 04	Infidelity and Marital Relationships: Death Knell or Wake-up Call?
Symposium 001	PTSD in Military Populations: Translating Research Into Practice
Symposium 002	Recent Research on Eating Disorders
Symposium 003	Smoking and Psychiatric Disorders: Clues About Causal Pathways and Innovative Treatment Approaches
Symposium 004	Shared Decision Making in Mental Health Care: A Recovery and Person-Centered Approach
Symposium 005	New Developments in Interpersonal Psychotherapy (IPT)
Symposium 006	Update on Treatments for Child and Adolescent Eating Disorders
Symposium 007	Neurodevelopmental Disorders in DSM-5: An Update from the Work Group
Symposium 008	Aggressive Behaviors in Geropsychiatric Patients: Neurobiology, Assessment and Management
Symposium 009	Advances in the Management of Treatment-Resistant Depression
Symposium 010	Clinical Trends in Bipolar Disorders
Symposium 011	Culturally Sensitive Assessment of Psychologically Distressed Ethnic and Non-English Speaking Populations
Symposium 012	Anxiety Treatment: New Research Findings for the Clinician
Symposium 013	Family and Behavioral Genetic Studies of Borderline Personality Disorder
Symposium 014	Examining the Outcome Continuum of Schizophrenia Into Later Life
Symposium 015	Spirituality and Mental Health: What is the Psychiatrist's Role?
Symposium 016	Burn Psychiatry: Treatment and Outcomes
Symposium 017	Update on Interventions for Adult Eating Disorders
Symposium 018	Translating the Psychopharmacology Evidence Base Into Practice: A Sampler From the American Society of Clinical Psychopharmacology
Symposium 019	Pathophysiology of Psychotic and Mood Disorders: Do We Have any Solid Evidence of Interest to Clinicians?
Symposium 020	Updating the APA Guidelines for the Treatment of Borderline Personality Disorder
Symposium 021	How to Get the Corner Office: Practical Leadership Strategies for Women Psychiatrists
Symposium 022	Culture and Psychiatric Diagnosis: Implications for the International Impact of DSM-5
Symposium 023	Recent Changes to Acute Psychiatric Care: An International Perspective
Symposium 024	Prevention of PTSD: Recent Israeli Practices
Symposium 025	Psychiatry Across Borders: Working for the U.S. Government in the Department of State as a Psychiatrist
Symposium 026	Transcultural Psychiatry for Mental Health in a Changing World
Symposium 027	Non Psychotic Issues of Schizophrenic Patients
Symposium 028	Doping in Athletes: The Role of the Sport Psychiatrist
Symposium 029	Executive Function as a Brain System for Self-Control: The Neurocircuitry of Psychiatric Disorders and Addiction
Symposium 030	Addiction Research, Prevention and Treatment in the U.S. and France: Vive la Difference!
Sunday, May 23
Lecture 03	Manfred S. Guttmacher Award Lecture: Patient Violence Against Mental Health Clinicians: Safety Assessment and Prevention
Scientific and Clinical Report 02	Mood Disorders
Scientific and Clinical Report 03	Psychpharmacology
Scientific and Clinical Report 04	Child and Adolescent Psychiatry
Scientific and Clinical Report 05	Psychosomatic Medicine and Health Services Research
Seminar 05	The IMG Institute
Seminar 06	Overview of Recovery for Psychiatrists
Symposium 031	Understanding Personality Disorders in Children and Adolescents: Current Status and Future Directions
Symposium 032	Treatment of Depression in Ethnic Minorities
Symposium 033	Approaches to Schizophrenia Through Phases of the Illness
Symposium 034	Diagnosing and Treating the Narcissistic Personality Disorder: Awaiting DSM-5
Symposium 035	Sex/Gender Differences and Women-Specific Issues in Drug Abuse: Predicting and Improving Treatment Outcomes
Symposium 036	Treating Chronic Pain and Co-Occuring Addiction in Substance Abuse Patients
Symposium 037	Culturally Sensitive Treatment of Psychologically Distressed Ethnic and Non-English Speaking Populations
Symposium 038	Neuroendocrine and Neuroimmunological Correlates of Bipolar Disorder in Women
Symposium 039	The Medical Home: Is There a Place for Psychiatry in it?
Symposium 040	Privacy in Electronic Medical Records
Monday, May 24
Advances In Medicine 01	Delirium: Neurobiology, Prevention and Treatment Approaches
Advances In Medicine 02	Top 10 Medical Articles of 2009: A Comprehensive and Practical Review of What We Need to Know
Advances In Research 01	Advances in Research
Advances In Series 01	Advances in Correctional Psychiatry: From Provision of Care to Malpractice Prevention
Advances In Series 02	Advances in Psychosomatic Medicine
Advances In Series 03	Advances in Forensic Psychiatry
Advances In Series 04	Advances in Psychotherapeutic Treatments
Focus	Focus Live 1 - Psychotherapy
Forum 01	Chopin at 200: His Mind and His Music
Forum 02	DSM-5: Progress in Research and Development
Lecture 04	APA/NIMH Vestermark Award Lecture - Why I Teach - Glen Gabbard, M.D.
Lecture 05	Distinguished Psychiatrist Lecture - The Perplexities & Provocations of Eating Disorders - Katherine Halmi, M.D.
Lecture 06	Optogenetics - Development and Application - Karl Deisseroth, M.D., Ph.D.
Lecture 07	Neuroimaging Clue to the Causes of Bipolar Disorder: Where We Are and Where We’re Going - Distinguished Psychiatrist Lecture
Lecture 08	Adolf Meyer Award Lecture - The Audacity Principle in Science?
Lecture 09	“Your Bipolar Dad Is a Bad Reason to Become a Psychiatrist”: Advocacy Adventures of a Bewildered Boy who Grew up to Become NAMI’s Medical Director - Patient Advocacy Award Lecture
Lecture 10	The Simple Truth About the Genetic Complexity of Schizophrenia
Lecture 11	Solomon Carter Fuller: What Would He Say about Racial Politics in American Psychiatry Today? Solomon Carter Fuller Award Lecture
Presidential Symposium 2	Comparative Effectiveness of Psychotropic Drugs: What Can We Learn from Practical Clinical Trials?
Presidential Symposium 3	Can Basic and Translational Neuroscience Improve Treatment in Psychiatry?
Scientific and Clinical Report 06	Psychotherapy and Depression
Scientific and Clinical Report 07	Borderline Personality Disorder and Emotion Dysregulation
Scientific and Clinical Report 08	Borderline Personality Disorder
Scientific and Clinical Report 09	Childhood Abuse
Scientific and Clinical Report 10	Cognitive Disorders
Scientific and Clinical Report 11	Diagnostic Issues and DSM-5
Scientific and Clinical Report 12	Psychosomatics and Cardiac Vulnerability
Scientific and Clinical Report 13	Addictive Behavior
Symposium 041	Health and Mental Health Around the World: Are all Systems Go?
Symposium 042	Update on Medications Development: Promising New Treatments for Drug Addiction
Symposium 043	Early Detection and Intervention in Schizophrenia: An Idea Whose Time has Come
Symposium 044	An Examination of CNS Trial Methodologies
Symposium 045 INVITED	Interpersonal and Social Rhythm Therapy (IPSRT) for Bipolar Disorder: New Applications, New Populations, and New Evidence
Symposium 046	Ensuring a Public Health Impact: Partnering With Consumers and Community Stakeholders to Improve Access and Quality of Care for Mental Disorders
Symposium 047	New Studies to Appear in the June Issue of the American Journal of Psychiatry: Presentations by the Authors and Editors
Symposium 048	Reducing Harm: SaferInjection and Other Strategies
Symposium 049	Advances in the Treatment of Bipolar Disorder
Symposium 050	Challenges in Providing Mental Health Care for College and University Students
Symposium 051	Geriatric Psychopharmacology of Late-Life Mood Disorders: Focus on the use of Biomarkers as Predictors of Response
Symposium 052	Innovations in Integrated Treatment of Substance Use and Psychiatric Disorders
Symposium 053	Genotypes and Biomarkers: The New Decision Makers for Tailored Treatment
Symposium 054	Substance Related Disorders in DSM-5: Progress Report
Symposium 055	DSM-5 Update Series, Part I: Reports From the Work Groups
Symposium 056	Focal Brain Stimulation for Psychiatric Disorders: Clinical Update
Symposium 057	Depression, Metabolic Syndrome and Obesity
Symposium 059	Neurobiology of Obesity: Why We Can Get Too Motivated to Eat
Tuesday, May 25
Advances in Medicine 03	Movement Disorders in Psychiatric Patients
Advances In Medicine 04	AM04 Aging and Dementia: An Update on Neuroscience
Advances In Medicine 05	Medical Mysteries and Practical Medical Psychiatric Updates: Is It Medical, Psychiatric, or a Little of Both?
Advances In Series 05	Family Assessment and Intervention for Psychiatrists
Advances In Series 06	Advances in the Use of Antipsychotic Medications
Advances In Series 07	Advances in Substance Abuse Treatment
Advances In Series 08	Advances In Personality Disorders
Forum 03	Is a Game-Changing Psychotropic Too Much to Expect?
Forum 04	Global Disasters: Lessons Learned from Haiti & New Orleans
Lecture 12	Addiction: Conflict Between Brain Circuits
Lecture 13	From Circuits to Cells to Molecular Regulation: Identifying Novel Targets for the Treatment of Psychotic Disorders
Lecture 14	Co-Morbidity of Psychiatric Disorders
Lecture 15	Highlights and Lessons from 40 Years in Psychiatry
Lecture 16	New Directions in Drug Policy: President Obama's National Demand Reduction Priorities - Special Guest Lecture, National Institute on Drug Abuse
Lecture 17	Toward a New Psychiatry: Valuing the Positive Emotions
Lecture 18	Prevention Initiatives in Schizophrenia
Lecture 19	Simon Bolivar Award Lecture - Depression and Suicidal Behavior in Latino Populations
Presidential Symposium 4	Recent Advances in Psychiatric Genetics: From Fundamental Discovery to Clinical Implication
Presidential Symposium 85	Health Reform and Psychiatry
Scientific and Clinical Report 14	Anxiety Disorders
Scientific and Clinical Report 15	Information Technology
Scientific and Clinical Report 16	SCR16-Side Effects of Psychotropic Medication
Scientific and Clinical Report 17	Weight Gain and Psychiatric Illness
Scientific and Clinical Report 18	Suicide
Scientific and Clinical Report 19	Attention Deficits and Psychostimulants
Scientific and Clinical Report 20	Inpatient Psychiatry: Admissions and Readmissions
Scientific and Clinical Report 21	Scales and Screening Measure
Symposium 060	The Potential and Pitfalls of Creating a Bipolar Genomic Biobank
Symposium 061	Psychiatrists in the World: Advocating for LGBT Mental Health
Symposium 062	The Public Health and Clinical Interface Between HIV, STDs, and Mental Health
Symposium 063	Adolescent Potential: Exploring the Developing Brain and Understanding Pathways of Addiction
Symposium 064	The 2010 APA Task Force Report on the Practice of Electroconvulsive Therapy: Evidence Based Guidelines for the Practicing Clinician
Symposium 065	DSM-5 Examined: Nosology of Mood Disorders
Symposium 066	DSM-5 Update Series, Part II: Reports From the Work Groups
Symposium 067	Revisiting Pharmacological Treatments to Prevent Suicide
Symposium 068	Reward Neurocircuitry in Substance Dependence and Other Psychiatric Disorders: What Does Brain Research Tell Us?
Symposium 069	Implementing the STEPPS* Program for Borderline Personality Disorder (*Systems Training for Emotional Predictability and Problem Solving)
Symposium 070	Evidence-Based Treatments (EBT) for Borderline Personality Disorder: Empirical Clarity Meets Clinical Reality
Symposium 072	The Nuts and Bolts of the Perinatal Psychiatric Consultation
Symposium 074	The Treatment of Psychiatric Disorders with rTMS: New Research and Clinical Findings
Symposium 075	The Tattered Safety Net: The Public Mental Health Crisis in an Economic Recession
Symposium 076	Lessons from Hurricane Katrina: Response, Recovery and Rebuilding
Symposium 077	Toward a New Model for Mental Health Services in the University Community
Symposium 078	DSM-5 Update Series, Part III: Reports from the Work Groups
Symposium 079	The Challenge of Cognitive Enhancers in Medicine
Symposium 080	Sex and Psychodynamics: Contemporary Approaches to Clinical Issues Through the Lifecycle
Symposium 081	Progress and Promise: Preventing the First Episode of Psychosis
Symposium 082	Reproductive Issues and Women’s Mental Health: How to Untie the Gordian Knot?
Symposium 083	Treatment of Depression With TMS: An Overview of Findings From the Optimization of TMS for the Treatment of Depression Trial (Opt-TMS)
Wednesday, May 26
Advances In Medicine 06	An Update on Gastroenterology and Hepatology for Psychiatrists and Mental Health Practitioners
Lecture 20	Administrative Psychiatry Award Lecture - So You Want to be a Physician Executive - Arthur Lazarus, M.D., M.B.A.
Lecture 21	Seek and Treat for Optimal Prevention of HIV/AIDS: STOP HIV/AIDS - Julio Montaner, M.D.
Scientific and Clinical Report 22	Genetics
Scientific and Clinical Report 23	Issues in Child and Adolescent Psychiatry
Scientific and Clinical Report 24	Antidepressant Response and Augmentation
Scientific and Clinical Report 25	Psychopharmacology
Scientific and Clinical Report 26	Psychosis
Scientific and Clinical Report 27	Issues in Mood Disorders
Scientific and Clinical Report 28	Epidemiology, Sleep, and Medical Screening
Scientific and Clinical Report 29	Important but Infrequently Addressed Topics
Seminar 07	Practical Guide to the Performance of the Mental Status Examination
Symposium 085	Women’s Mental Health in Latin America: Present and Future Research
Symposium 086	How Dysfunction of Learning and Memory Circuits Contribute to Substance Abuse and Other Psychiatric Disorders
Symposium 087	Advances in Psychiatric Ethics: New Approaches that Inform Psychiatric Practice
Symposium 088	ADHD FAQs: Practical Answers for the Office-Based Practicioner
Symposium 089	Autonomy in the Prolongation and Curtailment of Life
Symposium 090	New Perspectives on Intergenerational Transmission of BPD
Symposium 091	New CANMAT Guidelines for Depression and Bipolar Disorder: Combining Evidence with Clinical Practice
Symposium 092	Update on Cannabis Use Disorder
Symposium 093	Cultural Adaptation of Cognitive-Behavior Therapy for Ethnic/Minority Patients
Symposium 094	Choosing the Right Treatment for Substance Abuse
Symposium 095	Should “Risk syndrome of Psychosis” be Included in DSM-5 as a Diagnosis? A Road Toward Preventive Psychiatry
Symposium 096	Basic Science in Psychiatry: A Move Toward Translational Medicine
Symposium 097	The Supreme Court and Psychiatry in the 21st Century
Symposium 098	Novel Tools for Preventing and Treating Substance Use and Comorbidities in the Military and Returning Veterans
Symposium 099	Hot Topics in African-American Mental Health: Impact of Past and Current Prejudices; Women’s Mental Health; HIV; and Unique Psychopharmacological Findings
Symposium 100	Dysfunctions in Mentalization or Metacognition in Personality Disorders: Empirical Evidence and Implications for Pathology, Treatment and Research
Symposium 102	Treating Borderline Personality Disorder: Current Psychodynamic Perspectives
Symposium 103	Comprehensive HIV Psychiatry Update
Symposium 104	Understanding Comorbidity of Heart Disease With Depression and Anxiety Disorders
Symposium 105	The Ethics of Innovative Interventions in Psychiatry

*Tentative content. Subject to change. Individual sessions will be available as audio MP3 file downloads post-meeting at www.marathonmultimedia.com/store/apa

Tuesday, June 5, 2012

Alcohol and drug problems would be categorized differently in revised manual

By Michelle Andrews, Published: May 28

Topic Review: ADDICTIONS

Sunday, June 3, 2012

Psychiatric CME Sources Guide

FOCUS: The Journal of Lifelong Learning in Psychiatry

800-368-5777

Continue your lifelong learning with ONE trusted resource

2012 Annual Meeting

165th Annual MeetingMay 5-9, 2012Philadelphia, PA

Certificate of Attendance

APA ANNUAL MEETING sCIENTIFIC PROGRAM

APA GIVES BACK TO PHILADELPHIA

LOOKING FOR SESSION INFORMATION FOR THE APA 2012 ANNNUAL MEETING?

CLICK BELOW IMAGE TO DOWNLOAD .PDF

NEW!! You can now view the 2012 Annual Meeting Program Guide!!

PRESENTING A POSTER AT THE 2012 APA ANNUAL MEETING?

CONTINUING MEDICAL EDUCATION

165th Annual Meeting
May 5-9, 2012
Philadelphia, PA